Profile and clinical implication of circular RNAs in human papillary thyroid carcinoma

Background Differently expressed circular RNAs (circRNAs) have been reported to play a considerable role in tumor behavior; however, the expression profile and biological function of circRNAs in papillary thyroid carcinoma (PTC) remains unknown. Thus, the study was aimed to characterize the circRNA...

Full description

Bibliographic Details
Main Authors:	Huihui Ren, Zhelong Liu, Siyue Liu, Xinrong Zhou, Hong Wang, Jinchao Xu, Daowen Wang, Gang Yuan
Format:	Article
Language:	English
Published:	PeerJ Inc. 2018-08-01
Series:	PeerJ
Subjects:	Papillary thyroid carcinoma Biological marker Microarray BRAFV600E
Online Access:	https://peerj.com/articles/5363.pdf

Similar Items

Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules
by: Tatiana Marina Vieira Giorgenon, et al.
Published: (2019-03-01)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
by: Yan-Yu Lin, et al.
Published: (2023-01-01)

Rethinking the role of oncogenes in papillary thyroid cancer initiation
by: Mario eVitale
Published: (2012-06-01)

Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma
by: Qing Zhang, et al.
Published: (2016-02-01)

Association between BRAFV600E mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients
by: Havva Sezer, et al.
Published: (2020-08-01)

Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence
by: Taciana Padilha de Castro, et al.
Published: (2019-12-01)

BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters
by: Faruk Erdem KOMBAK, et al.
Published: (2019-05-01)

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
by: Dong Chen, et al.
Published: (2023-01-01)

Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
by: Xiaoquan Hong, et al.
Published: (2024-01-01)

T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma
by: Xubin Dong, et al.
Published: (2020-12-01)

X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
by: Sandeep Kumar Parvathareddy, et al.
Published: (2022-12-01)

Clinicopathological Implications of the BRAFV600E Mutation in Papillary Thyroid Carcinoma of Ukrainian Patients Exposed to the Chernobyl Radiation in Childhood: A Study for 30 Years After the Accident
by: Liudmyla Zurnadzhy, et al.
Published: (2022-04-01)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
by: Shuhui Huang, et al.
Published: (2022-11-01)

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
by: Harahap AS, et al.
Published: (2023-05-01)

The high degree of similarity in histopathological and clinical characteristics between radiogenic and sporadic papillary thyroid microcarcinomas in young patients
by: Tetiana Bogdanova, et al.
Published: (2022-08-01)

Hashimoto’s Thyroiditis: A “Double-Edged Sword” in Thyroid Carcinoma
by: Jiangyue Xu, et al.
Published: (2022-02-01)

Major Vault Protein (MVP) Associated With BRAFV600E Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways
by: Xubin Dong, et al.
Published: (2022-03-01)

Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy
by: Kirk Jensen, et al.
Published: (2020-08-01)

Analysis of Risk Factors Associated With Central Lymph Node Metastasis in Papillary Thyroid Carcinoma With cT1N0 Stage
by: Yin-zhu Zhao, et al.
Published: (2022-06-01)

Editorial: Recent advances in papillary thyroid carcinoma: Progression, treatment and survival predictors
by: Erivelto Martinho Volpi, et al.
Published: (2023-03-01)

Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
by: Qianqian Xu, et al.
Published: (2024-06-01)

BRAFV600E Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT
by: Yuan Gao, et al.
Published: (2022-05-01)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
by: Honglai Zhang, et al.
Published: (2018-10-01)

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
by: Yasemin Giles Şenyürek, et al.
Published: (2022-06-01)

Integrating BRAFV600E mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma
by: Zheng Zhang, et al.
Published: (2022-04-01)

Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas
by: Caroline Moraes Beltrami, et al.
Published: (2017-05-01)

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis
by: Yu Zhang, et al.
Published: (2022-03-01)

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy
by: Guoquan Zhu, et al.
Published: (2019-05-01)

BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
by: Xing Chen, et al.
Published: (2022-02-01)

AI‐BRAFV600E: A deep convolutional neural network for BRAFV600E mutation status prediction of thyroid nodules using ultrasound images
by: Chuang Xi, et al.
Published: (2023-04-01)

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules
by: Huang G, et al.
Published: (2023-12-01)

Autophagy-Related MicroRNA: Tumor miR-125b and Thyroid Cancers
by: Liudmila V. Spirina, et al.
Published: (2023-03-01)

Different Threshold of Malignancy for <i>RAS</i>-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice
by: Kennichi Kakudo
Published: (2022-02-01)

Current Advances in Papillary Craniopharyngioma: State-Of-The-Art Therapies and Overview of the Literature
by: Gianpaolo Jannelli, et al.
Published: (2023-03-01)

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
by: Emanuela Minna, et al.
Published: (2020-01-01)

Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer
by: Jingran Ji, et al.
Published: (2023-01-01)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
by: Osrodek M, et al.
Published: (2020-08-01)

A Review of Driver Genetic Alterations in Thyroid Cancers
by: Fatemeh Khatami, et al.
Published: (2018-04-01)

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
by: Noha Mukhtar, et al.
Published: (2023-10-01)